Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

References

• SenterPDPotent antibody drug conjugates for cancer therapyCurr Opin Chem Biol200913323524419414278
   PubMed Web of Science ®Google Scholar
• EvensAMHutchingsMDiehlVTreatment of Hodgkin lymphoma: the past, present, and futureNat Clin Pract Oncol20085954355618679394
   PubMedGoogle Scholar
• VoseJArmitageJWeisenburgerDInternational T-Cell Lymphoma ProjectInternational peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomesJ Clin Oncol200826254124413018626005
   PubMed Web of Science ®Google Scholar
• AnsellSMHorwitzSMEngertAPhase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphomaJ Clin Oncol200725192764276917515574
   PubMed Web of Science ®Google Scholar
• Forero-TorresALeonardJPYounesAA phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaBr J Haematol2009146217117919466965
   PubMed Web of Science ®Google Scholar
• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024122700443
   PubMed Web of Science ®Google Scholar
• KellyKMHodgsonDAppelBChildren’s Oncology Group’s 2013 blueprint for research: Hodgkin lymphomaPediatr Blood Cancer201360697297823255501
   PubMed Web of Science ®Google Scholar
• KanzlerHKüppersRHansmannMLRajewskyKHodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cellsJ Exp Med19961844149515058879220
   PubMed Web of Science ®Google Scholar
• KüppersRThe biology of Hodgkin’s lymphomaNat Rev Cancer200991152719078975
   PubMed Web of Science ®Google Scholar
• EichenauerDAEngertADreylingMESMO Guidelines Working GroupHodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201122Suppl 6vi55vi5821908505
   PubMed Web of Science ®Google Scholar
• LinchDCWinfieldDGoldstoneAHDose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trialLancet19933418852105110548096958
   PubMed Web of Science ®Google Scholar
• MajhailNSWeisdorfDJDeforTELong-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphomaBiol Blood Marrow Transplant200612101065107217084370
   PubMed Web of Science ®Google Scholar
• SchmitzNPfistnerBSextroMAggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trialLancet200235993232065207112086759
   PubMed Web of Science ®Google Scholar
• BurroughsLMO’DonnellPVSandmaierBMComparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphomaBiol Blood Marrow Transplant200814111279128718940683
   PubMed Web of Science ®Google Scholar
• CorradiniPDoderoAFarinaLAllogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeLeukemia200721112316232317597807
   PubMed Web of Science ®Google Scholar
• RamRGooleyTAMaloneyDGHistology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantationBiol Blood Marrow Transplant201117101537154521536145
   PubMed Web of Science ®Google Scholar
• SarinaBCastagnaLFarinaLAllogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availabilityBlood2010115183671367720220116
   PubMed Web of Science ®Google Scholar
• DawSWynnRWallaceHManagement of relapsed and refractory classical Hodgkin lymphoma in children and adolescentsBr J Haematol2011152324926021133886
   PubMed Web of Science ®Google Scholar
• FriedmanDIWoldenSConstineDLAHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the children’s oncology groupBlood (ASH Annu Meeting Abstr)2010116766
   Web of Science ®Google Scholar
• KellerFGNachmanJConstineLSA phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL)Blood (ASH Annu Meeting Abstr)2010116767
   Web of Science ®Google Scholar
• KellyKMSpostoRHutchinsonRBEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology GroupBlood201111792596260321079154
   PubMed Web of Science ®Google Scholar
• SchwartzCLConstineLSVillalunaDA risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Blood2009114102051205919584400
   PubMed Web of Science ®Google Scholar
• WoldenSLChenLKellyKMLong-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma – a report from the Children’s Oncology GroupJ Clin Oncol201230263174318022649136
   PubMed Web of Science ®Google Scholar
• MerkelOHamacherFSifftEKennerLGreilREuropean Research Initiative on Anaplastic Large Cell LymphomaNovel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological toolsMol Cancer Ther20111071127113621712478
   PubMed Web of Science ®Google Scholar
• WebbTRSlavishJGeorgeREAnaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapyExpert Rev Anticancer Ther20099333135619275511
   PubMed Web of Science ®Google Scholar
• FerreriAJGoviSPileriSASavageKJAnaplastic large cell lymphoma, ALK-negativeCrit Rev Oncol Hematol201385220621522789917
   PubMed Web of Science ®Google Scholar
• LoweEJGrossTGAnaplastic large cell lymphoma in children and adolescentsPediatr Hematol Oncol201330650951923758281
   PubMed Web of Science ®Google Scholar
• LamantLde ReynièsADuplantierMMGene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypesBlood200710952156216417077326
   PubMed Web of Science ®Google Scholar
• SavageKJHarrisNLVoseJMInternational Peripheral T-Cell Lymphoma ProjectALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectBlood2008111125496550418385450
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth EditionLyonIARC Press2008
   Google Scholar
• FossFMZinzaniPLVoseJMGascoyneRDRosenSTTobinaiKPeripheral T-cell lymphomaBlood2011117256756676721493798
   PubMed Web of Science ®Google Scholar
• SibonDFournierMBrièreJLong-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trialsJ Clin Oncol201230323939394623045585
   PubMed Web of Science ®Google Scholar
• SchmitzNTrümperLZiepertMTreatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study GroupBlood2010116183418342520660290
   PubMed Web of Science ®Google Scholar
• SuzukiRKagamiYTakeuchiKPrognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotypeBlood20009692993300011049976
   PubMed Web of Science ®Google Scholar
• O’ConnorOAProBPinter-BrownLPralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyJ Clin Oncol20112991182118921245435
   PubMed Web of Science ®Google Scholar
• MosseYPBalisFMLimMSEfficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children’s Oncology Group phase I consortium studyJ Clin Oncol (ASCO Annu Meeting Abstr)2012309500
   Web of Science ®Google Scholar
• Gambacorti-PasseriniCMessaCPoglianiEMCrizotinib in anaplastic large-cell lymphomaN Engl J Med2011364877577621345110
   PubMed Web of Science ®Google Scholar
• PoglianiEMDildaIVillaFHigh response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patientsJ Clin Oncol (ASCO Annu Meeting Abstr)201129e18507
   Google Scholar
• BrugièresLLe DeleyMCRosolenAImpact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL GroupJ Clin Oncol200927689790319139435
   PubMed Web of Science ®Google Scholar
• LamantLMcCarthyKd’AmoreEPrognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 studyJ Clin Oncol201129354669467622084369
   PubMed Web of Science ®Google Scholar
• Le DeleyMCReiterAWilliamsDEuropean Intergroup for Childhood Non-Hodgkin LymphomaPrognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup studyBlood200811131560156617957029
   PubMed Web of Science ®Google Scholar
• DuckettCSGedrichRWGilfillanMCThompsonCBInduction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2Mol Cell Biol1997173153515429032281
   PubMed Web of Science ®Google Scholar
• LeeSYParkCGChoiYT cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factorsJ Exp Med199618326696748627180
   PubMed Web of Science ®Google Scholar
• MirSSRichterBWDuckettCSDifferential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cellsBlood200096134307431211110706
   PubMed Web of Science ®Google Scholar
• YounesAAggarwallBBClinical implications of the tumor necrosis factor family in benign and malignant hematologic disordersCancer200398345846712879461
   PubMed Web of Science ®Google Scholar
• NadaliGTavecchiaLZanolinESerum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcomeBlood1998918301130169531614
   PubMed Web of Science ®Google Scholar
• ViscoCNadaliGVassilakopoulosTPVery high levels of soluble CD30 recognize the patients with classical Hodgkin’s lymphoma retaining a very poor prognosisEur J Haematol200677538739416879607
   PubMed Web of Science ®Google Scholar
• ZanottiRTroleseAAmbrosettiASerum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin’s lymphomaAnn Oncol200213121908191412453859
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPileriSBendandiMClinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patientsJ Clin Oncol1998164153215379552063
   PubMed Web of Science ®Google Scholar
• HorieRWatanabeTCD30: expression and function in health and diseaseSemin Immunol19981064574709826579
   PubMed Web of Science ®Google Scholar
• TarkowskiMExpression and a role of CD30 in regulation of T-cell activityCurr Opin Hematol200310426727112799531
   PubMed Web of Science ®Google Scholar
• KempfWPfaltzKVermeerMHEORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphomaBlood2011118154024403521841159
   PubMed Web of Science ®Google Scholar
• YounesACarboneACD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disordersInt J Biol Markers199914313514310569134
   PubMed Web of Science ®Google Scholar
• EdingerJTClarkBZPucevichBEGeskinLJSwerdlowSHCD30 expression and proliferative fraction in nontransformed mycosis fungoidesAm J Surg Pathol200933121860186819898220
   PubMed Web of Science ®Google Scholar
• GerberHPEmerging immunotherapies targeting CD30 in Hodgkin’s lymphomaBiochem Pharmacol201079111544155220096666
   PubMed Web of Science ®Google Scholar
• BorchmannPTremlJFHansenHThe human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaBlood2003102103737374212881320
   PubMed Web of Science ®Google Scholar
• HeuckFEllermannJBorchmannPCombination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesJ Immunother200427534735315314543
   PubMed Web of Science ®Google Scholar
• WahlAFKlussmanKThompsonJDThe anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s diseaseCancer Res200262133736374212097283
   PubMed Web of Science ®Google Scholar
• CardarelliPMMoldovan-LoomisMCPrestonBIn vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphomaClin Cancer Res200915103376338319401346
   PubMed Web of Science ®Google Scholar
• HammondPWVafaOJacintoJA humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor bindingBlood (ASH Annu Meeting Abstr)20051061470
   Web of Science ®Google Scholar
• LawrenceCEHammondPWZalevskyJXMAbTM2513, an Fc engineering humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignanciesBlood (ASH Annu Meeting Abstr)20071102340
   Google Scholar
• ThertulienRFrankelAEvensAMA phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human anti-CD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin’s lymphomaAACR Meeting Abstr20091227
   Google Scholar
• BlumKASmithMFungHPhase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogeninicty, and efficacyJ Clin Oncol (ASCO Annu Meeting Abstr)20092715S8531
   Google Scholar
• YounesAZalevskyJBlumKAEvaluation of the pharmacokinetics, immunogenicity, and safety of XmAb(R)2513 in the ongoing study XmAb2513-2501: a phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphomaBlood (ASH Annu Meeting Abstr)20081125012
   Google Scholar
• FranciscoJACervenyCGMeyerDLcAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activityBlood200310241458146512714494
   PubMed Web of Science ®Google Scholar
• DubowchikGMMosureKKnipeJOFirestoneRACathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicinBioorg Med Chem Lett1998823334733529873732
   PubMed Web of Science ®Google Scholar
• SandersonRJHeringMAJamesSFIn vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugateClin Cancer Res2005112 Pt 184385215701875
   PubMed Web of Science ®Google Scholar
• OkeleyNMMiyamotoJBZhangXIntracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugateClin Cancer Res201016388889720086002
   PubMed Web of Science ®Google Scholar
• GrussHJPintoAGloghiniACD30 ligand expression in nonmalignant and Hodgkin’s disease-involved lymphoid tissuesAm J Pathol199614924694818701986
   PubMed Web of Science ®Google Scholar
• PintoAAldinucciDGloghiniAHuman eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin’s disease cell lineBlood1996889329933058896393
   PubMed Web of Science ®Google Scholar
• TheurichSMalcherJWennholdKBrentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remissionJ Clin Oncol2013315e59e6323269992
   PubMed Web of Science ®Google Scholar
• HamblettKJSenterPDChaceDFEffects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateClin Cancer Res200410207063707015501986
   PubMed Web of Science ®Google Scholar
• McDonaghCFTurcottEWestendorfLEngineered antibody-drug conjugates with defined sites and stoichiometries of drug attachmentProtein Eng Des Sel200619729930716644914
   PubMed Web of Science ®Google Scholar
• OflazogluEKisslerKMSieversELGrewalISGerberHPCombination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphomaBr J Haematol20081421697318477046
   PubMed Web of Science ®Google Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• FanaleMAForero-TorresARosenblattJDA phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignanciesClin Cancer Res201218124825522080439
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePBrentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyJ Clin Oncol201230182190219622614995
   PubMed Web of Science ®Google Scholar
• YounesAGopalAKSmithSEResults of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphomaJ Clin Oncol201230182183218922454421
   PubMed Web of Science ®Google Scholar
• ChesonBDPfistnerBJuweidMEInternational Harmonization Project on LymphomaRevised response criteria for malignant lymphomaJ Clin Oncol200725557958617242396
   PubMed Web of Science ®Google Scholar
• de ClaroRAMcGinnKKwitkowskiVU.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphomaClin Cancer Res201218215845584922962441
   PubMed Web of Science ®Google Scholar
• RotheASasseSGoergenHBrentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experienceBlood201212071470147222786877
   PubMed Web of Science ®Google Scholar
• GibbAJonesCBloorABrentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerHaematologica201398461161423065511
   PubMed Web of Science ®Google Scholar
• ChenRPalmerJMThomasSHBrentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphomaBlood2012119266379638122611160
   PubMed Web of Science ®Google Scholar
• GopalAKRamchandrenRO’ConnorOASafety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationBlood2012120356056822510871
   PubMed Web of Science ®Google Scholar
• SasseSRotheAGoergenHBrentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphomaLeuk Lymphoma201354102144214823402268
   PubMed Web of Science ®Google Scholar
• Seattle Genetics IncBrentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Available from: http://clinicaltrials.gov/show/NCT01461538. NLM identifier: NCT01461538Accessed November 20, 2013
   Google Scholar
• AlbanyCFeldmanDRGarboLEEinhornLHAntitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumorsJ Clin Oncol201331Suppl 6 abstr 327
   Web of Science ®Google Scholar
• Seattle Genetics IncA Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) Available from: http://clinicaltrials.gov/show/NCT01100502. NLM identifier: NCT01100502Accessed November 20, 2013
   Google Scholar
• Millennium Pharmaceuticals IncPhase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Available from: http://clinicaltrials.gov/show/NCT01712490. NLM identifier: NCT01712490Accessed November 20, 2013
   Google Scholar
• Seattle Genetics IncECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Available from: http://clinicaltrials.gov/show/NCT01777152. NLM identifier: NCT01777152Accessed November 20, 2013
   Google Scholar
• National Cancer Institute (NCI)Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Available from: http://clinicaltrials.gov/show/NCT01780662. NLM identifier: NCT01780662Accessed November 20, 2013
   Google Scholar
• St. Jude Children’s Research HospitalAdcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma Available from: http://clinicaltrials.gov/show/NCT01920932. NLM identifier: NCT01920932Accessed November 20, 2013
   Google Scholar
• Millennium Pharmaceuticals IncStudy of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Available from: http://clinicaltrials.gov/show/NCT01492088. NLM identifier: NCT01492088Accessed November 20, 2013
   Google Scholar
• Seattle Genetics IncA Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Available from: http://clinicaltrials.gov/show/NCT01421667. NLM identifier: NCT01421667Accessed November 20, 2013
   Google Scholar
• M.D. Anderson Cancer CenterSGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) Available from: http://clinicaltrials.gov/show/NCT01352520. NLM identifier: NCT01352520Accessed November 20, 2013
   Google Scholar
• Seattle Genetics IncStudy of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Available from: http://clinicaltrials.gov/show/NCT01925612. NLM identifier: NCT01925612Accessed November 20, 2013
   Google Scholar
• Fondazione MichelangeloBrentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors Available from: http://clinicaltrials.gov/show/NCT01851200. NLM identifier: NCT01851200Accessed November 20, 2013
   Google Scholar
• KimYounPilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level Available from: http://clinicaltrials.gov/show/NCT01396070. NLM identifier: NCT01396070Accessed November 20, 2013
   Google Scholar
• Stanford UniversityBrentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Available from: http://clinicaltrials.gov/show/NCT01807598. NLM identifier: NCT01807598Accessed November 20, 2013
   Google Scholar
• Washington University School of MedicineBrentuximab Vedotin Prevention of (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation Available from: http://clinicaltrials.gov/show/NCT01700751. NLM identifier: NCT01700751Accessed November 20, 2013
   Google Scholar
• Seattle Genetics IncA Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms Available from: http://clinicaltrials.gov/show/NCT01309789. NLM identifier: NCT01309789Accessed November 20, 2013
   Google Scholar